Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.

Prognostic value of RASSF1 promoter methylation in prostate cancer.

Daniunaite K, Jarmalaite S, Kalinauskaite N, Petroska D, Laurinavicius A, Lazutka JR, Jankevicius F.

J Urol. 2014 Dec;192(6):1849-55. doi: 10.1016/j.juro.2014.06.075. Epub 2014 Jun 26.

PMID:
24980613
2.

Frequent methylation of RASSF1 and RARB in urine sediments from patients with early stage prostate cancer.

Daniūnaitė K, Berezniakovas A, Jankevičius F, Laurinavičius A, Lazutka JR, Jarmalaitė S.

Medicina (Kaunas). 2011;47(3):147-53. English, Lithuanian.

3.

Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer.

Bañez LL, Sun L, van Leenders GJ, Wheeler TM, Bangma CH, Freedland SJ, Ittmann MM, Lark AL, Madden JF, Hartman A, Weiss G, Castaños-Vélez E.

J Urol. 2010 Jul;184(1):149-56. doi: 10.1016/j.juro.2010.03.012. Epub 2010 May 15.

PMID:
20478579
4.

Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy.

Rosenbaum E, Hoque MO, Cohen Y, Zahurak M, Eisenberger MA, Epstein JI, Partin AW, Sidransky D.

Clin Cancer Res. 2005 Dec 1;11(23):8321-5.

5.

DNA methylation of the PITX2 gene promoter region is a strong independent prognostic marker of biochemical recurrence in patients with prostate cancer after radical prostatectomy.

Weiss G, Cottrell S, Distler J, Schatz P, Kristiansen G, Ittmann M, Haefliger C, Lesche R, Hartmann A, Corman J, Wheeler T.

J Urol. 2009 Apr;181(4):1678-85. doi: 10.1016/j.juro.2008.11.120. Epub 2009 Feb 23.

PMID:
19233404
6.

Methylation of multiple genes in prostate cancer and the relationship with clinicopathological features of disease.

Singal R, Ferdinand L, Reis IM, Schlesselman JJ.

Oncol Rep. 2004 Sep;12(3):631-7.

PMID:
15289848
7.

Heterogeneity of DNA methylation in multifocal prostate cancer.

Serenaite I, Daniunaite K, Jankevicius F, Laurinavicius A, Petroska D, Lazutka JR, Jarmalaite S.

Virchows Arch. 2015 Jan;466(1):53-9. doi: 10.1007/s00428-014-1678-3. Epub 2014 Nov 5.

PMID:
25369892
8.

GSTP1 promoter methylation is associated with recurrence in early stage prostate cancer.

Maldonado L, Brait M, Loyo M, Sullenberger L, Wang K, Peskoe SB, Rosenbaum E, Howard R, Toubaji A, Albadine R, Netto GJ, Hoque MO, Platz EA, Sidransky D.

J Urol. 2014 Nov;192(5):1542-8. doi: 10.1016/j.juro.2014.04.082. Epub 2014 Apr 21.

9.

Development and clinical validation of a real-time PCR assay for PITX2 DNA methylation to predict prostate-specific antigen recurrence in prostate cancer patients following radical prostatectomy.

Dietrich D, Hasinger O, Bañez LL, Sun L, van Leenders GJ, Wheeler TM, Bangma CH, Wernert N, Perner S, Freedland SJ, Corman JM, Ittmann MM, Lark AL, Madden JF, Hartmann A, Schatz P, Kristiansen G.

J Mol Diagn. 2013 Mar;15(2):270-9. doi: 10.1016/j.jmoldx.2012.11.002. Epub 2012 Dec 22.

PMID:
23266319
10.

Discovery and validation of 3 novel DNA methylation markers of prostate cancer prognosis.

Cottrell S, Jung K, Kristiansen G, Eltze E, Semjonow A, Ittmann M, Hartmann A, Stamey T, Haefliger C, Weiss G.

J Urol. 2007 May;177(5):1753-8.

PMID:
17437806
11.

Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer.

Jerónimo C, Usadel H, Henrique R, Silva C, Oliveira J, Lopes C, Sidransky D.

Urology. 2002 Dec;60(6):1131-5.

PMID:
12475696
12.

Methylation of PITX2, HOXD3, RASSF1 and TDRD1 predicts biochemical recurrence in high-risk prostate cancer.

Litovkin K, Joniau S, Lerut E, Laenen A, Gevaert O, Spahn M, Kneitz B, Isebaert S, Haustermans K, Beullens M, Van Eynde A, Bollen M.

J Cancer Res Clin Oncol. 2014 Nov;140(11):1849-61. doi: 10.1007/s00432-014-1738-8. Epub 2014 Jun 18.

PMID:
24938434
13.

Genetic and epigenetic SLC18A2 silencing in prostate cancer is an independent adverse predictor of biochemical recurrence after radical prostatectomy.

Sørensen KD, Wild PJ, Mortezavi A, Adolf K, Tørring N, Heebøll S, Ulhøi BP, Ottosen P, Sulser T, Hermanns T, Moch H, Borre M, Ørntoft TF, Dyrskjøt L.

Clin Cancer Res. 2009 Feb 15;15(4):1400-10. doi: 10.1158/1078-0432.CCR-08-2268.

14.

Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci.

Bastian PJ, Ellinger J, Wellmann A, Wernert N, Heukamp LC, Müller SC, von Ruecker A.

Clin Cancer Res. 2005 Jun 1;11(11):4097-106.

15.

Multigene methylation analysis for detection and staging of prostate cancer.

Enokida H, Shiina H, Urakami S, Igawa M, Ogishima T, Li LC, Kawahara M, Nakagawa M, Kane CJ, Carroll PR, Dahiya R.

Clin Cancer Res. 2005 Sep 15;11(18):6582-8.

16.

Prognostic value of CpG island hypermethylation at PTGS2, RAR-beta, EDNRB, and other gene loci in patients undergoing radical prostatectomy.

Bastian PJ, Ellinger J, Heukamp LC, Kahl P, Müller SC, von Rücker A.

Eur Urol. 2007 Mar;51(3):665-74; discussion 674. Epub 2006 Aug 23.

PMID:
16956712
17.

AIM1 promoter hypermethylation as a predictor of decreased risk of recurrence following radical prostatectomy.

Rosenbaum E, Begum S, Brait M, Zahurak M, Maldonado L, Mangold LA, Eisenberger MA, Epstein JI, Partin AW, Sidransky D, Hoque MO.

Prostate. 2012 Jul 1;72(10):1133-9. doi: 10.1002/pros.22461. Epub 2011 Nov 29.

18.

Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects.

Hoque MO, Topaloglu O, Begum S, Henrique R, Rosenbaum E, Van Criekinge W, Westra WH, Sidransky D.

J Clin Oncol. 2005 Sep 20;23(27):6569-75.

PMID:
16170165
19.

Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy.

Bastian PJ, Palapattu GS, Lin X, Yegnasubramanian S, Mangold LA, Trock B, Eisenberger MA, Partin AW, Nelson WG.

Clin Cancer Res. 2005 Jun 1;11(11):4037-43.

20.

Supplemental Content

Support Center